Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC By Ogkologos - October 29, 2025 277 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Advances in Treating Kidney Cancer and Metastatic Prostate Cancer: Research from... January 25, 2024 Father Dances With Joy After Learning His Son Is Cancer Free November 14, 2021 Speaking a thousand words – how a cancer image collection is... September 8, 2021 FDA Grants Accelerated Approval to Sunvozertinib for Metastatic Non-Small Cell Lung... July 25, 2025 Load more HOT NEWS Experimental mRNA Vaccine Hints at Potential Against Glioblastoma Tips from Your Cancer Care Team – Coping with Treatment During... Modest Population-Level Increases in Survival Observed After Implementation of Immune Checkpoint... A Single Colonoscopy Reduces CRC Risk, but Not CRC Mortality
